Tuesday, March 28, 2023
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
DiYeargan-Bate Professor of Medicine Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director
Institute for Global Health and Infectious Diseases
Chief
Division of Infectious Diseases
University of North Carolina at Chapel Hill
Professor and Chair
Population Health Science and Medicine
University of Mississippi Medical Center
Jackson, Mississippi
Associate Professor of Medicine
Director
Student Employee Health Services
Morehouse School of Medicine
Atlanta, Georgia
Associate Director, Accreditation and Compliance
Medscape, LLC
This activity is intended for primary care physicians, infectious diseases/HIV specialists, and public health and preventive medicine specialists.
The goal of this activity is to improve knowledge regarding the benefits of treatment as prevention (TasP) for patients living with HIV and the best practices for implementing TasP in clinical practice.
Upon completion of this activity, participants will:
As an organization accredited by the ACCME, Medscape, LLC, requires everyone who is in a position to control the content of an education activity to disclose all relevant financial relationships with any commercial interest. The ACCME defines "relevant financial relationships" as financial relationships in any amount, occurring within the past 12 months, including financial relationships of a spouse or life partner, that could create a conflict of interest.
Medscape, LLC, encourages Authors to identify investigational products or off-label uses of products regulated by the US Food and Drug Administration, at first mention and where appropriate in the content.
DiYeargan-Bate Professor of Medicine Microbiology and Epidemiology
Associate Vice Chancellor for Medical Affairs and Global Health
Director
Institute for Global Health and Infectious Diseases
Chief
Division of Infectious Diseases
University of North Carolina at Chapel Hill
Professor and Chair
Population Health Science and Medicine
University of Mississippi Medical Center
Jackson, Mississippi
Associate Professor of Medicine
Director
Student Employee Health Services
Morehouse School of Medicine
Atlanta, Georgia
Associate Director, Accreditation and Compliance
Medscape, LLC
Medscape, LLC designates this enduring material for a maximum of 1.0
AMA PRA Category 1 Credit(s)™
. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Medscape, LLC staff have disclosed that they have no relevant financial relationships.
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit. Aggregate participant data will be shared with commercial supporters of this activity.
Awarded 1.0 contact hour(s) of continuing nursing education for RNs and APNs; 0.5 contact hours are in the area of pharmacology.
Medscape, LLC designates this continuing education activity for 1.0 contact hour(s) (0.100 CEUs) (Universal Activity Number JA0007105-0000-21-438-H01-P).
For questions regarding the content of this activity, contact the accredited provider for this CME/CE activity noted above. For technical assistance, contact [email protected]
There are no fees for participating in or receiving credit for this online educational activity. For information on applicability
and acceptance of continuing education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within the time designated on the title page; physicians should claim only those
credits that reflect the time actually spent in the activity. To successfully earn credit, participants must complete the
activity online during the valid credit period that is noted on the title page. To receive AMA PRA Category 1 Credit™, you must receive a minimum score of 75% on the post-test.
Follow these steps to earn CME/CE credit*:
You may now view or print the certificate from your CME/CE Tracker. You may print the certificate but you cannot alter it.
Credits will be tallied in your CME/CE Tracker and archived for 6 years; at any point within this time period you can print
out the tally as well as the certificates from the CME/CE Tracker.
*The credit that you receive is based on your user profile.
CME / ABIM MOC / CE Released: 7/25/2019; Reviewed and Renewed: 7/27/2021
Valid for credit through: 7/27/2022
processing....
Alberts B. Science breakthroughs. Science. 2011;334:1604-1604.
Auld AF, Agizer T, Mathoma A, et al. Effect of TB screening and retention interventions on early ART mortality in Botswana. Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 4–7, 2019; Seattle, WA. Abstract 31.
Baeten JM, Kahle E, Lingappa JR, et al. Genital HIV-1 RNA predicts risk of heterosexual HIV-1 transmission. Sci Transl Med. 2011;3:77ra29.
Bavinton BR, Pinto AN, Phanuphak N, et al. Viral suppression and HIV transmission in serodiscordant male couples: an international, prospective, observational, cohort study. Lancet HIV. 2018;5:e438-e447.
Centers for Disease Control and Prevention. HIV in the Southern United States. May 2016. Available at: https://www.cdc.gov/hiv/pdf/policies/cdc-hiv-in-the-south-issue-brief.pdf. Accessed July 5, 2019.
Centers for Disease Control and Prevention. National Prevention Information Network. Maps based on data from 2017 HIV surveillance report. Available at: https://www.cdc.gov/hiv/pdf/library/slidesets/cdc-hiv-us-maps-2017.pdf. Accessed July 5, 2019.
Centers for Disease Control and Prevention. Understanding the HIV care continuum. June 2018. Available at: https://www.cdc.gov/hiv/pdf/library/factsheets/cdc-hiv-care-continuum.pdf. Accessed July 5, 2019.
Centers for Disease Control and Prevention. HIV/AIDS: HIV basics. Living with HIV. Available at: https://www.cdc.gov/hiv/basics/livingwithhiv/index.html. Accessed July 5, 2019.
Centers for Disease Control and Prevention. HIV in the United States by region. November 2018. Available at: https://www.cdc.gov/hiv/pdf/statistics/overview/cdc-hiv-geographic-distribution.pdf. Accessed July 5, 2019.
Centers for Disease Control and Prevention. Evidence of HIV treatment and viral suppression in preventing the sexual transmission of HIV. December 2018. Available at: https://www.cdc.gov/hiv/pdf/risk/art/cdc-hiv-art-viral-suppression.pdf. Accessed July 5, 2019.
Centers for Disease Control and Prevention. HIV/AIDS Statistics Center. HIV in the United States and dependent areas. January 2019. Available at: Https://www.cdc.gov/hiv/statistics/overview/ataglance.html. Accessed July 5, 2019.
Centers for Disease Control and Prevention. Health Disparities in HIV/AIDS, viral hepatitis, STDs, and TB. Available at: https://www.cdc.gov/nchhstp/healthdisparities/default.htm. Accessed July 5, 2019.
Centers for Disease Control and Prevention. National Prevention Information Network. Selected national HIV prevention and care outcomes. Available at: https://www.cdc.gov/hiv/pdf/library/slidesets/cdc-hiv-prevention-and-care-outcomes.pdf. Accessed July 5, 2019.
Centers for Disease Control and Prevention. Facts about HIV stigma. Available at: https://www.cdc.gov/actagainstaids/campaigns/lsht/hiv-stigma-facts/index.html. Accessed July 5, 2019.
Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365:493-505.
Cohen MS. Treatment for HIV prevention, one couple at a time. Lancet HIV. 2018;5:e408-e409.
Cohen MS. Successful treatment of HIV eliminates sexual transmission. Lancet. 2019;393:2366-2367.
Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med. 1994;331:1173-1180.
Danel C, Moh R, Gabillard D, et al. A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med. 2015;373:808-822.
Eisinger RW, Fauci AS. Ending the HIV/AIDS pandemic. Emerg Infect Dis. 2018;24:413-416.
Eisinger RW, Dieffenbach CW, Fauci AS. HIV viral load and transmissibility of HIV infection: undetectable equals untransmittable. JAMA. 2019;321:451-452.
Fauci AS, Redfield RR, Sigounas G, et al. Ending the HIV epidemic: a plan for the United States. JAMA. 2019;321:844-845.
Fischl MA, Richman DD, Grieco MH, et al. The efficacy of azidothymidine (AZT) in the treatment of patients with AIDS and AIDS-related complex. A double-blind, placebo-controlled trial. N Engl J Med. 1987;317:185-191.
Galvin SR, Cohen MS. The role of sexually transmitted diseases in HIV transmission. Nat Rev Microbiol. 2004;2:33-42.
Gardner EM, McLees MP, Steiner JF, Del Rio C, Burman WJ. The spectrum of engagement in HIV care and its relevance to test-and-treat strategies for prevention of HIV infection. Clin Infect Dis. 2011;52:793-800.
Havlir D, Charlebois E, Balzer L, et al. SEARCH community cluster randomized study of HIV "test and treat" using multi- disease approach and streamlined care in rural Uganda and Kenya. Presented at: 22nd International AIDS Conference (AIDS 2018); July 23-27, 2018; Amsterdam, the Netherlands. Abstract 13469.
Hayes RJ, Donnell DJ, Floyd S, et al. Impact of universal testing and treatment in Zambia and South Africa: HPTN071 (PopART). Presented at: Conference on Retroviruses and Opportunistic Infections (CROI); March 4–7, 2019; Seattle, WA. Abstract 92.
HIV.gov. What is 'Ending the HIV Epidemic: A Plan for America'? February 2019. Available at: https://www.hiv.gov/federal-response/ending-the-hiv-epidemic/overview. Accessed July 5, 2019.
Justman JE, Mugurungi O, El-Sadr WM. HIV Population surveys -- bringing precision to the global response. N Engl J Med. 2018;378:1859-1861.
Larmarange J, Diallo MH, McGrath N, et al. C. Temporal trends of population viral suppression in the context of Universal Test and Treat: results from the ANRS 12249 TasP trial in rural South Africa. Presented at: 22nd International AIDS Conference (AIDS 2018); July 23-27, 2018; Amsterdam, the Netherlands.
Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373:795-807.
Neiman AB, Ruppar T, Ho M, et al. CDC Grand rounds: improving medication adherence for chronic disease management -- innovations and opportunities. Am J Transplant. 2018;18:514-517.
National Center for Chronic Disease Prevention and Health Promotion. Health equity. Available at: https://www.cdc.gov/chronicdisease/healthequity/index.htm. Accessed July 5, 2019.
National LGBT Health Education Center. Available at: https://www.lgbthealtheducation.org/. Accessed July 5, 2019.
Ng HH. intersectionality and shared decision making in LGBTQ health. LGBT Health. 2016;3:325-326.
Office of Disease Prevention and Health Prevention. Social determinants of health. Available at: https://www.healthypeople.gov/2020/topics-objectives/topic/social-determinants-of-health. Accessed July 5, 2019.
Patel P, Borkowf CB, Brooks JT, et al. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28:1509-1519.
Quinn TC, Wawer MJ, Sewankambo N, et al. Viral load and heterosexual transmission of human immunodeficiency virus type 1. Rakai Project Study Group. N Engl J Med. 2000;342:921-929.
Rodger AJ, Cambiano V, Bruun T, et al. Sexual activity without condoms and risk of HIV transmission in serodifferent couples when the HIV-positive partner is using suppressive antiretroviral therapy. Jama. 2016;316:171-181..
Rodger AJ, Cambiano V, Bruun T, et al. Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. Lancet. 2019;393:2428-2438.
Saag MS, Benson CA, Gandhi RT, et al. Antiretroviral drugs for treatment and prevention of HIV infection in adults: 2018 recommendations of the International Antiviral Society-USA Panel. JAMA. 2018;320:379-396.
Samji H, Cescon A, Hogg RS, et al. Closing the gap: increases in life expectancy among treated HIV-positive individuals in the United States and Canada. PLoS One. 2013;8:e81355.
Severe P, Jean Juste MA, Ambroise A, et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med. 2010;363:257-265.
Southern AIDS Coalition. Southern states manifesto: update 2008. Available at: https://southernaidscoalition.org/wp-content/uploads/2017/03/Southern-States-Manifesto-20081.pdf. Accessed July 5, 2019.
Tanser F, Barnighausen T, Grapsa E, et al. High coverage of ART associated with decline in risk of HIV acquisition in rural KwaZulu-Natal, South Africa. Science. 2013;339:966-971.
University of California San Francisco. Thirty years of AIDS: a timeline of the epidemic . Available at: https://www.ucsf.edu/news/2011/06/9971/thirty-years-aids-timeline-epidemic. Accessed July 5, 2019.
US DHHS AIDS info. Available at: https://aidsinfo.nih.gov/understanding-hiv-aids/infographics/25/fda-approval-of-hiv-medicines. Accessed May 7, 2019.
World Health Organization. Treat all people living with HIV, offer antiretrovirals as additional prevention choice for people at "substantial" risk. Available at: https://www.who.int/mediacentre/news/releases/2015/hiv-treat-all-recommendation/en/. Accessed July 5, 2019.
| « Return to: Treatment as Prevention |
